MDMA treatment

The U.S. Patent and Trademark Office (USPTO) has granted PharmAla Biotech Holdings (OTC:MDXXF) a national patent covering the composition of matter of its lead novel compound, ALA-002.   The Novel Chemical Entity (NCE) is among the group of MDXX-class molecules under development by the biotech....

Can Psychedelics Increase Sexual Interest And Satisfaction? Study Says Yes And Effects Can Last Months A new study suggests a potential link between the use of psychedelics like magic mushrooms and LSD and improved sexual function up to six months after they have been consumed. Believed to be the...

Welcome to Benzinga's weekly psychedelics news roundup. We have pulled together several must-read news items from the last week of December 2023 and the first of January 2024.  Research Disorders due to substance use: Hallucinogens and MDMA-related...

Melbourne will soon open Clarion Clinics’ first exclusively dedicated facility to provide psychedelic-assisted therapies legalized in Australia.  The subsidiary to biotech Incannex Healthcare (NASDAQ: IXHL) received the required Human Research Ethics Committee (HREC) endorsement for...

Biden To Decide On Psychedelic Therapy Bill President Joe Biden received the final version of a large-scale defense bill providing funding for psychedelics clinical trials for military service members. The section calls on the Department of Defense (DOD) to establish a process for active duty...

Australian Coalition Calls For Psychedelic Rules Review Following roughly five months since the country’s Therapeutic Goods Administration (TGA) officially enabled the prescription of MDMA and psilocybin-assisted therapies for certain mental health conditions, a new coalition of healthcare...

The first of several of PharmAla Biotech’s (OTC: PMBHF) shipments of psychedelic molecules -both API and finished drug product capsules- to its Australian JV Cortexa for use under the Authorized Prescriber Scheme (APS) is all set. The Canadian MDXX class molecules company, together with...

Clinical-stage psychedelics biotech Mind Medicine (MindMed) (NASDAQ: MNMD) has shared its financial outcomes for the third quarter ended September 30, 2023. In numbers: Cash and cash equivalents of $117.7 million by Sept. 30, a 17.2% decrease from the $142.1 million held by Dec. 31, 2022 and a...

Canadian biotech company PharmAla Biotech Holdings (OTC: PMBHF) has filed a patent covering composition of matter of Novel Chemical Entity (NCE) PharmAla-1.  PharmAla-1 was discovered through computational in-silico modeling exercises via an innovation grant-funded partnership with University...

Former child star and one of the beloved Charlie’s Angels, Drew Barrymore hinted that she would consider MDMA or psilocybin therapy “as a way to get to some state where I could see things in a different way.” As hostess of The Drew Barrymore Show, she encourages guests to...

New York-based biotech Terran Biosciences has signed an agreement with French pharmaceutical company Pierre Fabre Médicament for worldwide exclusive rights to develop and commercialize a list of the latter's assets targeting neuropsychiatric conditions. The licensing deal includes...

The American Medical Association (AMA) is expected to issue the first code for psychedelic therapy reimbursement, following the approval of a joint application submitted by MAPS PBC and COMPASS Pathways (NASDAQ: CMPS). On March 3, the AMA published its Panel Actions summary which included the...

Psychedelics biotech Mydecine Innovations Group (OTC: MYCOF) is advancing the development of its novel compounds family of next-gen MDMA analogs. So far, Mydecine's compounds show promising pharmacokinetics (PK) and pharmacodynamics (PD) in preclinical models.  The new data on the MYCO-006...

A bipartisan legislative effort led by Rep. Dan Crenshaw aims to urge the participation of active-duty servicemembers in the National Institutes of Health (NIH)-funded research with psychedelics. The letter, directed to an appropriations subcommittee on Labor, HHS, Education and Related...

Clinical-stage biopharma company Mind Medicine (MindMed), Inc. (NASDAQ: MNMD) shared its financial results for the full year ended Dec. 31, 2022. Numbers show solid stability: Yearly operating activities expenses of $50.1 million, R&D expenses of $36.2 million and general and...